View More
Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Jeremy S. Abramson, MD, MMSc, discusses highlights of the key data from ASH 2020 on the treatment of patients with lymphomas/CLL, with topics including:
Presenters:
Jeremy S. Abramson, MD, MMSc
Associate Professor
Department of Medicine
Harvard Medical School
Director, Center for Lymphoma
Massachusetts General Hospital
Boston, Massachusetts
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
On-demand webcast from an ASH 2022 satellite symposium on BTK inhibitors for patients with CLL and MCL, from Clinical Care Options (CCO)
Jeff Sharman, MD
Ian W. Flinn, MD, PhD
Susan M. O'Brien, MD
Physicians:
maximum of 2.0 AMA PRA Category 1 Credits™
Released: January 31, 2023
Expired:
January 30, 2024
On-demand Clinical Care Options (CCO) webcast from a December 2022 symposium: experts discuss new care standards and evolving treatment strategies for aggressive B-cell lymphomas
John P. Leonard, MD
John Allan, MD
Laurie H. Sehn, MD, MPH
Physicians:
maximum of 2.0 AMA PRA Category 1 Credits™
Released: January 30, 2023
Expired:
January 29, 2024
In this commentary, experts review key aspects of contemporary treatment for CLL, from Clinical Care Options (CCO)
Deborah Stephens, DO
Jennifer Woyach, MD
Released: January 30, 2023
On-demand webcast from an ASH 2022 satellite symposium on asparaginase for the treatment of AYA and adult acute lymphoblastic leukemia, from Clinical Care Options (CCO)
Daniel J. DeAngelo, MD, PhD
Emily Curran, MD
Kjeld Schmiegelow, MD, DMSci
Physicians:
maximum of 2.0 AMA PRA Category 1 Credits™
Released: January 30, 2023
Expired:
January 29, 2024
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.